Comparison of auditory hallucinations across different disorders and syndromes

Neuropsychiatry

Volumn 2, Issue 1, 2012, Pages 57-68

  Sommer, Iris Ec ^a   Koops, Sanne ^a   Blom, Jan Dirk ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c PARNASSIA BAVO GROEP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PIMOZIDE; PLACEBO; RISPERIDONE; ZONISAMIDE;

AFFECTIVE PSYCHOSIS; ALZHEIMER DISEASE; ANTICONVULSANT THERAPY; AUDITORY HALLUCINATION; BORDERLINE STATE; COMORBIDITY; DELIRIUM; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG FATALITY; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EPILEPSY; HALLUCINATION; HEARING IMPAIRMENT; HUMAN; HUNTINGTON CHOREA; MANIA; MENTAL DISEASE; MIGRAINE; MIGRAINE AURA; NEUROLOGIC DISEASE; ORGANIC PSYCHOSYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RELIGION; REVIEW; SCHIZOPHRENIA; SENSORY DEPRIVATION; SOMATIZATION; SUBSTANCE ABUSE; TEMPORAL LOBE EPILEPSY; UNSPECIFIED SIDE EFFECT; VISUAL DEPRIVATION; VISUAL HALLUCINATION;

EID: 84876511437     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.12.2     Document Type: Review

References (69)

1. Sartorius N, Jablensky A, Korten A et al. Early manifestations and first-contact incidence of schizophrenia in different cultures: a preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol. Med. 16(4), 909-928 (1986).
2. Nayani TH, David AS. The auditory hallucination: a phenomenological survey. Psychol. Med. 26, 177-189 (1996). (Pubitemid 26031813)
3. Bracha HS, Wolkowitz OM, Lohr JB, Karson CN, Bigelow LB. High prevalence of visual hallucinations in research subjects with chronic schizophrenia. Am. J. Psychiatry 146, 526-528 (1989). (Pubitemid 19099307)
4. Al-Issa I. Social and cultural aspects of hallucinations. Psychol. Bull. 3, 570-587 (1977).
5. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br. J. Psychiatry 151, 145-151 (1987). (Pubitemid 17102086)
6. Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, Copolov DL. Positive and negative symptoms in the psychoses: multidimensional scaling of SAPS and SANS items. Schizophr. Res. 8(2), 143-156 (1992).
7. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch. Gen. Psychiatry 52(5), 341-351 (1995).
8. Peters E, Joseph S, Day S, Garety P. Measuring delusional ideation: the 21-item Peters et al. Delusions Inventory (PDI). Schizophr. Bull. 30(4), 1005-1022 (2004). (Pubitemid 40469533)
9. Sommer IE, Derwort AMC, Daalman K, de Weijer AD, Liddle PF, Boks MPM. Formal thought disorder in non-clinical individuals with auditory verbal hallucinations. Schizophr. Res. 118(1-3), 140-145 (2010).
10. Falkai P. Differential diagnosis in acute psychotic episode. Int. Clin. Psychopharmacol. 11(Suppl. 2), 13-17 (1996).
11. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550 (2001). (Pubitemid 32695238)
12. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 56(10), 940-945 (1999). (Pubitemid 29480131)
13. Stoudemire A, Linfors E, Houpt JL. Central nervous system sarcoidosis. Gen. Hosp. Psychiatry 5, 129-132 (1983). (Pubitemid 13050994)
14. Boyd MC, Stainbok P, Paty DW. Familial arteriovenous malformations: report of four cases in one family. J. Neurosurg. 62, 597-599 (1985). (Pubitemid 15079429)
15. Sax KW, Strakowski SM, McElroy SL et al. Attention and formal thought disorder in mixed and pure mania. Biol. Psychiatry 37(6), 420-423 (1995).
16. Ianzito BM, Cadoret RJ, Pugh DD. Thought disorder in depression. Am. J. Psychiatry 131(6), 703-707 (1974).
17. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr. Psychiatry doi:10.1016/j. comppsych.2011.03.009 (2011) (Epub ahead of print).
18. Gournellis R, Oulis P, Rizos E, Chourdaki E, Gouzaris A, Lykouras L. Clinical correlates of age of onset in psychotic depression. Arch. Gerontol. Geriatr. 52(1), 94-98 (2011).
19. Andreasen NC, Grove WM. Thought, language, and communication in schizophrenia: diagnosis and prognosis. Schizophr. Bull. 12(3), 348-359 (1986).
20. Kingdon DG, Ashcroft K, Bhandari B et al. Schizophrenia and borderline personality disorder: similarities and differences in the experience of auditory hallucinations, paranoia, and childhood trauma. J. Nerv. Ment. Dis. 198(6), 399-403 (2010).
21. Slotema CW, Daalman K, Blom JD, Diederen KMJ, Hoek HW, Sommer IE. Auditory verbal hallucinations in patients with borderline personality disorder are similar to those in schizophrenia. Psychol. Med. (2012) (In press).
22. Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J. Clin. Psychopharmacol. 31(4), 489-496 (2011).
23. Beavan V, Read J, Cartwright C. The prevalence of voice-hearers in the general population: a literature review. J. Ment. Health 20(3), 281-292 (2011).
24. Sommer IE, Daalman K, Rietkerk T et al. Healthy individuals with auditory verbal hallucinations; who are they? Psychiatric assessments of a selected sample of 103 subjects. Schizophr. Bull. 36(3), 633-641 (2010).
25. Blom JD, Eker H, Basalan H, Aouaj Y, Hoek HW. [Hallucinations attributed to djinns]. Ned. Tijdschr. Geneeskd, 154, A973, 2010).
26. Blom JD, Hoffer C. Djinns. In: Hallucinations. Research and Practice. Blom JD, Sommer IEC (Eds). Springer, NY, USA, 235-253 (2011).
27. Daalman K, Boks MPM, Diederen KMJ et al. The same or different? Auditory verbal hallucinations in healthy and psychotic individuals. J. Clin. Psychiatry 72(3), 320-325 (2011).
28. Forsaa EB, Larsen JP, Wentzel-Larsen T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67, 996-1001 (2010).
29. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J. Neurol. Sci. 15, 12-17 (2010).
30. Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331-342 (2009).
31. Ballard C, McKeith I, Harrison R et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int. Psychogeriatr. 9(4), 381-388 (1997). (Pubitemid 28197427)
32. Nagahama Y, Okina T, Suzuki N, Matsuda M. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 133(Pt 2), 557-567 (2010).
33. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat. Disord. 16(9), 553-560 (2010).
34. Poewe W. When a Parkinson's disease patient starts to hallucinate. Pract. Neurol. 8, 238-241 (2008).
35. Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ. Hallucinations in neurodegenerative diseases. CNS Neurosci. Ther. doi:10.1111/j.1755-5949. 00247.x. (2011) (Epub ahead of print).
36. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J. Nerv. Ment. Dis. 172, 521-528 (1984). (Pubitemid 14019613)
37. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113-1124 (1996). (Pubitemid 26374873)
38. Blom JD. A Dictionary of Hallucinations. Springer, NY, USA (2010).
39. Boettger S, Passik S, Breitbart W. Delirium superimposed on dementia versus delirium in the absence of dementia: phenomenological differences. Palliat. Support. Care 7(4), 495-500 (2009).
40. Van Eijk MM, Roes KC, Honing ML et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 376, 1829-1837 (2010).
41. Spalletta G, Musicco M, Padovani A et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 18, 1026-1035 (2010).
42. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 129(Pt 3), 729-735 (2006). (Pubitemid 43278234)
43. Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. J. Psychiatr. Res. 38(1), 105-111 (2004). (Pubitemid 38018992)
44. Garre-Olmo J, López-Pousa S, Vilalta-Franch J, de Gracia Blanco M, Vilarrasa AB. Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer's disease, part I: symptom clusters. J. Alzheimers Dis. 22(4), 1157-1167 (2010).
45. Scarmeas N, Brandt J, Albert M et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch. Neurol. 62(10), 1601-1608 (2005). (Pubitemid 41434568)
46. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am. J. Psychiatry 162(11), 1996-2021 (2005). (Pubitemid 41598254)
47. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 17, 100-108 (2004). (Pubitemid 37499973)
48. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J. Clin. Psychiatry 69(3), 341-348 (2008). (Pubitemid 351549385)
49. Kalapatapu RK, Schimming C. Update on neuropsychiatric symptoms of dementia: antipsychotic use. Geriatrics 64, 10-18 (2009).
50. Folstein SE, Folstein MF. Psychiatric features of Huntington's disease: recent approaches and findings. Psychiatr. Dev. 1(2), 193-205 (1983).
51. Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. 58(2), 273-278 (2001). (Pubitemid 32163165)
52. Salluh JI, Soares M, Teles JM et al. Delirium Epidemiology in Critical Care (DECCA): an international study. Critical Care 14, R210 (2010).
53. Kuehn BM. Delirium often not recognized or treated despite serious long-term consequences. JAMA 28, 389-395 (2010).
54. Meagher DJ, Moran M, Raju B et al. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br. J. Psychiatry 190, 135-141 (2007).
55. Schreiber W, Pauls AM, Krieg JC. [Toxic psychosis as an acute manifestation of diphenhydramine poisoning]. Dtsch Med. Wochenschr. 113(5), 180-183 (1988). (Pubitemid 18065851)
56. Young J, Murthy L, Westby M, Akunne A, O'Mahony R. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ 341, C3704 (2010).
57. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 40(Suppl. 10), S2-S20 (1999).
58. Alper KR, Barry JJ, Balabanov AJ. Treatment of psychosis, aggression, and irritability in patients with epilepsy. Epilepsy Behav. 3, 13-18 (2002).
59. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 25(2), 91-110 (2002). (Pubitemid 34261185)
60. Daniel C, Donnet A. Migrainous complex hallucinations in a 17-year-old adolescent. Headache 51(6), 999-1001 (2011).
61. Menon GJ, Rahman I, Menon SJ, Dutton GN. Complex visual hallucinations in the visually impaired: the Charles Bonnet syndrome. Surv. Ophthalmol. 48, 58-72 (2003). (Pubitemid 36136084)
62. Cope TE, Baguley DM. Is musical hallucination an otological phenomenon? A review of the literature. Clin. Otolaryngol. 34, 423-430 (2009).
63. Pasquini F, Cole MG. Idiopathic musical hallucinations in the elderly. J. Geriatr. Psychiatry Neurol. 10, 11-14 (1997). (Pubitemid 27186850)
64. Tuerlings JHAM, Wijnen H, Boerman R, Verwey B. [Music as an uninvited guest: the auditory variant of the Charles Bonnet syndrome]. Tijdschr. Psychiatr. 51, 853-858 (2009).
65. David RR, Fernandez HH. Quetiapine for hypnagogic musical release hallucinations. J. Geriatr. Psychiatry Neurol. 13, 210-211 (2000). (Pubitemid 32055169)
66. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J. Am. Geriatr. Soc. 58, 1027-1034 (2010).
67. Rosenthal RN, Miner CR. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorders. Schizophr. Bull. 23(2), 187-193 (1997). (Pubitemid 27224871)
68. Kulick AR, Ahmed I. Substance-induced organic mental disorders: a clinical and conceptual approach. Gen. Hosp. Psychiatry 8, 168-172 (1986). (Pubitemid 16122655)
69. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264(19), 2511-2519 (1990).